MedTrace Logo

Patient Blood Management in Patients Scheduled for Cardiac Surgery

NCT06637137 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 464

Last updated 2025-02-26

No results posted yet for this study

Summary

The ICARUS 2 study has the general objective of collecting data in patients undergoing cardiac surgery; in our centre, in order to optimize and improve hemoglobin values, a team of haematologists, assisted by cardio anesthetists and cardiac surgeons, will evaluate the blood tests of patients scheduled for elective cardiac surgery in order to correct any states of hypoferritinemia (low iron in the blood) to promote recovery from blood losses related to cardiac surgery. This objective is strongly encouraged by the good use of blood programs currently in force at our foundation.

In particular, the research presented here intends to demonstrate a reduction in the number of intra- and post-operative transfusions.

Conditions

  • Anemia
  • Anemia, Iron-Deficiency
  • Iron Deficiency Anemia Treatment
  • Iron Deficiency Anemia (IDA)
  • Cardiac Surgical Patients
  • Blood Loss, Surgical

Interventions

DRUG

Iron

Patients who present a state of hypoferritinemia or a state of reduced transferrin saturation will undergo administration of i.v iron at least 2 weeks before scheduled cardiac surgery, plus acid folic and B vitamin co-administration.

Sponsors & Collaborators

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    lead OTHER

Principal Investigators

  • luciana Teofili, Phd · Fondazione Policlinico Gemelli, IRCCS

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-24
Primary Completion
2027-02-28
Completion
2027-02-28

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06637137 on ClinicalTrials.gov